⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5507726 | 0.97 | — | — | |
| SCHEMBL341630 | 0.81 | CYP2C19 (0.47) | — | |
| SCHEMBL11184089 | 0.75 | CYP2C19 (0.37) | — | |
| SCHEMBL158019 | 0.75 | — | — | |
| SCHEMBL17340316 | 0.74 | — | — | |
| Bromide SCHEMBL11876625 | 0.73 | — | — | |
| SCHEMBL352634 | 0.73 | — | — | |
| SCHEMBL14042508 | 0.72 | — | — | |
| SCHEMBL14199821 | 0.72 | — | — | |
| SCHEMBL8738527 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200408765-A1 | NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2020-12-31 | — | — | US | claimed |
| US-RE47123-E1 | EPHA2 receptor antagonist antibodies | SANOFI (FR) | 2018-11-13 | — | — | US | claimed |
| EP-2044122-B1 | ANTAGONIST ANTIBODY AGAINST EPHA2 FOR THE TREATMENT OF CANCER | SANOFI SA (FR) | 2018-03-28 | — | — | EP | claimed |
| US-20150274824-A1 | ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER | SANOFI-AVENTIS (FR) | 2015-10-01 | — | — | US | claimed |
| US-8992912-B2 | Methods of use for antibodies that specifically bind to the EphA2 receptor | SANOFI (FR) | 2015-03-31 | — | — | US | claimed |
| US-20130302316-A1 | ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER | SANOFI-AVENTIS (FR) | 2013-11-14 | — | — | US | claimed |
| US-8460667-B2 | EPHA2 receptor antagonist antibodies | SANOFI (FR) | 2013-06-11 | — | — | US | claimed |
| EP-2540320-A1 | LEPTOMYCIN DERIVATIVES | SANOFI (FR) | 2013-01-02 | — | — | EP | claimed |
| US-20120156218-A1 | NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER | SANOFI-AVENTIS (FR) | 2012-06-21 | — | — | US | claimed |
| EP-2032172-B1 | LEPTOMYCIN DERIVATIVES | SANOFI SA (FR) | 2012-06-06 | — | — | EP | claimed |
| US-20090182038-A1 | Leptomycin Derivatives | SANOFI-AVENTIS (FR) | 2009-07-16 | — | — | US | claimed |
| EP-2076540-A2 | NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER | Sanofi-Aventis (FR) | 2009-07-08 | — | — | EP | claimed |
| EP-2044122-A2 | ANTAGONIST ANTIBODY AGAINST EPHA2 FOR THE TREATMENT OF CANCER | Sanofi-Aventis (FR) | 2009-04-08 | — | — | EP | claimed |
| EP-2032172-A2 | LEPTOMYCIN DERIVATIVES | Sanofi-Aventis (FR) | 2009-03-11 | — | — | EP | claimed |
| WO-2008047242-A9 | NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER | SANOFI AVENTIS (FR) | 2009-02-05 | — | — | WO | claimed |
| WO-2008010101-A9 | ANTAGONIST ANTIBODY AGAINST EPHA2 FOR THE TREATMENT OF CANCER | SANOFI AVENTIS (DE) | 2009-01-29 | — | — | WO | claimed |
| WO-2008047242-A2 | NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER | SANOFI-AVENTIS (FR) | 2008-04-24 | — | — | WO | claimed |
| WO-2008010101-A2 | ANTAGONIST ANTIBODY AGAINST EPHA2 FOR THE TREATMENT OF CANCER | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | WO | claimed |
| WO-2007144709-A2 | LEPTOMYCIN DERIVATIVES | SANOFI-AVENTIS (FR) | 2007-12-21 | — | — | WO | claimed |
| EP-1864682-A1 | Leptomycin derivatives | Sanofi-Aventis (FR) | 2007-12-12 | — | — | EP | claimed |